Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253446 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5489748 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19102433 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20936054 | 0.73 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL15329364 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11134639 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL12499138 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20170088 | 0.68 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL14564596 | 0.67 | SMN1; SMN2 (0.40) | SMN1; SMN2GLAKMT2AL3MBTL1 | |
| SCHEMBL20170045 | 0.67 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235885-A1 | COMPOSITION AND METHOD FOR INHIBITING POLYMERIZATION AND POLYMER GROWTH | Uniroyal Chemical Company, Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| WO-2001040404-A1 | COMPOSITION AND METHOD FOR INHIBITING POLYMERIZATION AND POLYMER GROWTH | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9303034-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-06-25 | — | — | US | disclosed |
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2015-06-25 | — | — | US | disclosed |
| EP-1794106-A1 | SULFONATED PHENOLS WITH NITROPHENOLS AS POLYMERIZATION INHIBITORS | Chemtura Corporation (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2006036274-A1 | SULFONATED PHENOLS WITH NITROPHENOLS AS POLYMERIZATION INHIBITORS | CHEMTURA CORPORATION (US) | 2006-04-06 | — | — | WO | disclosed |
| EP-1248757-A1 | INHIBITION OF POLYMERIZATION OF UNSATURATED MONOMERS | Uniroyal Chemical Company, Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001053235-A1 | INHIBITION OF POLYMERIZATION OF UNSATURATED MONOMERS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175613-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | SMN1; SMN2 2449/4885GLA 1811/4885KMT2A 3260/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | SMN1; SMN2 1471/4885GLA 2323/4885KMT2A 735/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | SMN1; SMN2 2449/4885GLA 1811/4885KMT2A 3260/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMN1; SMN2 705/4885GLA 1449/4885KMT2A 2041/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | SMN1; SMN2 2449/4885GLA 1811/4885KMT2A 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.